Lytix Biopharma AS (STU:6BG) Beta: -1.2757 (As of Jul. 07, 2026)


STU:6BG Lytix Biopharma AS STU:6BG
30 GF Score
Price €0.80
GF Value €0.01
! 2 Warning Signs
View Full Analysis

What is Lytix Biopharma AS Beta?

Lytix Biopharma AS STU:6BG -3.37% 30 Beta is -1.2757 as of Jul. 07, 2026. GuruFocus rates STU:6BG with a GF Score™ of 30/100 and a GF Value™ of €0.01. The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-07), Lytix Biopharma AS's Beta is -1.2757.


Lytix Biopharma AS  (STU:6BG) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Lytix Biopharma AS Beta Related Terms


Lytix Biopharma AS Beta Historical Data

* Premium members only.

The historical data trend for Lytix Biopharma AS's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lytix Biopharma AS Beta Chart

Lytix Biopharma AS Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 -0.38 -1.75

Lytix Biopharma AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.79 -1.07 -1.75 -1.75 -1.84

STU:6BG vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Lytix Biopharma AS's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lytix Biopharma AS Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lytix Biopharma AS's Beta distribution charts can be found below:

* The bar in red indicates where Lytix Biopharma AS's Beta falls into.


STU:6BG
30GF Score
Lytix Biopharma AS STU:6BG
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lytix Biopharma AS Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of -1.2757 mean?
Lytix Biopharma AS (STU:6BG) has a Beta of -1.2757 as of Jul. 07, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lytix Biopharma AS and its competitors.
Is Lytix Biopharma AS's Beta too high?
Lytix Biopharma AS's current Beta is -1.2757. Overall, Lytix Biopharma AS has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Lytix Biopharma AS's Beta compare to VRTX and REGN?
Lytix Biopharma AS's Beta of -1.2757 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Lytix Biopharma AS and its competitors. Lytix Biopharma AS's current Beta is -1.2757. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lytix Biopharma AS stock overvalued right now?
Lytix Biopharma AS (STU:6BG) has a current Beta of -1.2757. The stock's GF Value™ is €0.01, compared to a current price of €0.80 — trading 7940% above its estimated fair value. The current Beta is -1.2757. Lytix Biopharma AS's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Lytix Biopharma AS (STU:6BG), the current Beta is -1.2757 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lytix Biopharma AS (STU:6BG) Overvalued in 2026?

Based on GuruFocus' analysis, Lytix Biopharma AS stock appears to be overvalued. The current stock price of €0.80 is trading 7940% above its estimated GF Value™ of €0.01.

Key valuation signals for STU:6BG:

  • Beta: -1.2757
  • GF Value™: €0.01 vs. price of €0.80 (7940% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the STU:6BG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Lytix Biopharma AS Business Description

Other Exchanges LYTIX:Norway
Address Sandakerveien 138, Oslo, NOR, 0484
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. The company's technology platform is designed to convert immunologically "cold" tumors into "hot" tumors by releasing tumor antigens and activating tumor-specific immune responses. The product pipeline of the company includes LTX-401 and LTX-315. The company operates in Norway and the USA, majority of revenue is from the USA.
30GF Score

Get the complete analysis for STU:6BG

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price
€0.01
GF Value